Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Valneva shares slump after the companies said the study's primary endpoint didn't meet statistical significance Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine.

(Bloomberg) -- Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is ...

Dec 9 (Reuters) - Pfizer said ‌on Tuesday it ‌had entered into an ⁠exclusive ‌licensing agreement with ‍YaoPharma, a subsidiary of Shanghai Fosun ‌Pharmaceutical, for the development and ...

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers.

TRENTON, N.J. (AP) -- The drugmaker Pfizer Inc. and nearly a dozen health advocacy groups want to help senior citizens and younger people talk about a subject many find frightening or at least ...

HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for ...

New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...

Pharmaceutical giant Pfizer and French partner Valneva said they plan to seek regulatory approval for a Lyme disease vaccine after sharing mixed results from a late-stage trial. The companies said ...